Network Meta-analysis of Stem cell therapy for Erectile dysfunction secondary to cavernous nerve injury in rats and humans
BAUS ePoster online library. WANI M. 06/23/21; 319043; p13-5
Disclosure(s): This study did not receive any grant.
Mr. MUDASSIR WANI
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Discussion Forum (0)
Rate & Comment (0)
Introduction
We carried out systemic review and network meta-analysis to investigate role of stem cell therapy (SCT) in management of erectile dysfunction (ED) secondary to cavernous nerve injury in rats and humans.
Patients and Methods
After registration with PROSPERO database, we searched studies analyzing efficacy of SCT for ED due to bilateral cavernous nerve injury (BCNI) in rats using HDAS Export software (Medline, EMBASE, Scopus) from inception to September 2020. Twenty nine animal studies were included with outcome measurements being; Intracavernosal pressure (ICP), ICP/MAP (Mean arterial pressure) ratio and histological changes. All available human trials evaluating SCT in post prostatectomy patients were also assessed for International Index for erectile function (IIEF Score) and Erection Hardness Score (EHS).
Results:
For ICP measurement, studies were divided into Adipose derived stem cells (ADSC) subgroup and Bone marrow derived stem cells (BMSC) subgroup. Pooled analysis of these studies showed a beneficial effect of SCT in improving erectile function in rats with BCNI using network meta-analysis (95% CI, p<0.001). There was increase in ICP/MAP ratio in stem cell groups (including co-intervention) compared to control BCNI group. Histological evaluation of penile tissue revealed an increase in neuronal nitric oxide synthase (nNOS), smooth muscle content and anti-apoptotic activity. Human trials revealed improved IIEF and EHS.
Conclusions:
Our results confirm that stem cell therapy does improve the erectile function in rats having cavernous nerve injury. Further, co-interventions and specific modifications do improve efficacy of stem cell therapy. Similarly, early human results have shown promising results.
We carried out systemic review and network meta-analysis to investigate role of stem cell therapy (SCT) in management of erectile dysfunction (ED) secondary to cavernous nerve injury in rats and humans.
Patients and Methods
After registration with PROSPERO database, we searched studies analyzing efficacy of SCT for ED due to bilateral cavernous nerve injury (BCNI) in rats using HDAS Export software (Medline, EMBASE, Scopus) from inception to September 2020. Twenty nine animal studies were included with outcome measurements being; Intracavernosal pressure (ICP), ICP/MAP (Mean arterial pressure) ratio and histological changes. All available human trials evaluating SCT in post prostatectomy patients were also assessed for International Index for erectile function (IIEF Score) and Erection Hardness Score (EHS).
Results:
For ICP measurement, studies were divided into Adipose derived stem cells (ADSC) subgroup and Bone marrow derived stem cells (BMSC) subgroup. Pooled analysis of these studies showed a beneficial effect of SCT in improving erectile function in rats with BCNI using network meta-analysis (95% CI, p<0.001). There was increase in ICP/MAP ratio in stem cell groups (including co-intervention) compared to control BCNI group. Histological evaluation of penile tissue revealed an increase in neuronal nitric oxide synthase (nNOS), smooth muscle content and anti-apoptotic activity. Human trials revealed improved IIEF and EHS.
Conclusions:
Our results confirm that stem cell therapy does improve the erectile function in rats having cavernous nerve injury. Further, co-interventions and specific modifications do improve efficacy of stem cell therapy. Similarly, early human results have shown promising results.
Introduction
We carried out systemic review and network meta-analysis to investigate role of stem cell therapy (SCT) in management of erectile dysfunction (ED) secondary to cavernous nerve injury in rats and humans.
Patients and Methods
After registration with PROSPERO database, we searched studies analyzing efficacy of SCT for ED due to bilateral cavernous nerve injury (BCNI) in rats using HDAS Export software (Medline, EMBASE, Scopus) from inception to September 2020. Twenty nine animal studies were included with outcome measurements being; Intracavernosal pressure (ICP), ICP/MAP (Mean arterial pressure) ratio and histological changes. All available human trials evaluating SCT in post prostatectomy patients were also assessed for International Index for erectile function (IIEF Score) and Erection Hardness Score (EHS).
Results:
For ICP measurement, studies were divided into Adipose derived stem cells (ADSC) subgroup and Bone marrow derived stem cells (BMSC) subgroup. Pooled analysis of these studies showed a beneficial effect of SCT in improving erectile function in rats with BCNI using network meta-analysis (95% CI, p<0.001). There was increase in ICP/MAP ratio in stem cell groups (including co-intervention) compared to control BCNI group. Histological evaluation of penile tissue revealed an increase in neuronal nitric oxide synthase (nNOS), smooth muscle content and anti-apoptotic activity. Human trials revealed improved IIEF and EHS.
Conclusions:
Our results confirm that stem cell therapy does improve the erectile function in rats having cavernous nerve injury. Further, co-interventions and specific modifications do improve efficacy of stem cell therapy. Similarly, early human results have shown promising results.
We carried out systemic review and network meta-analysis to investigate role of stem cell therapy (SCT) in management of erectile dysfunction (ED) secondary to cavernous nerve injury in rats and humans.
Patients and Methods
After registration with PROSPERO database, we searched studies analyzing efficacy of SCT for ED due to bilateral cavernous nerve injury (BCNI) in rats using HDAS Export software (Medline, EMBASE, Scopus) from inception to September 2020. Twenty nine animal studies were included with outcome measurements being; Intracavernosal pressure (ICP), ICP/MAP (Mean arterial pressure) ratio and histological changes. All available human trials evaluating SCT in post prostatectomy patients were also assessed for International Index for erectile function (IIEF Score) and Erection Hardness Score (EHS).
Results:
For ICP measurement, studies were divided into Adipose derived stem cells (ADSC) subgroup and Bone marrow derived stem cells (BMSC) subgroup. Pooled analysis of these studies showed a beneficial effect of SCT in improving erectile function in rats with BCNI using network meta-analysis (95% CI, p<0.001). There was increase in ICP/MAP ratio in stem cell groups (including co-intervention) compared to control BCNI group. Histological evaluation of penile tissue revealed an increase in neuronal nitric oxide synthase (nNOS), smooth muscle content and anti-apoptotic activity. Human trials revealed improved IIEF and EHS.
Conclusions:
Our results confirm that stem cell therapy does improve the erectile function in rats having cavernous nerve injury. Further, co-interventions and specific modifications do improve efficacy of stem cell therapy. Similarly, early human results have shown promising results.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}